ALKEM Alkem Lab Q1 FY26 results (Apr–Jun 2025) and concall
Alkem Lab reported a strong Q1 FY26, with double-digit revenue and profit growth driven by robust performance in both India and international markets. The company's EBITDA margin expanded to 21.9%, reflecting disciplined strategy execution. While new initiatives like MedTech are expected to incur initial losses, management expressed confidence in their long-term growth potential and maintained full-year guidance despite anticipated higher R&D and opex in later quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 | 3,371 |
| EBITDA | 753 | 759 | 391 | 739 |
| Net profit | 702 | 641 | 322 | 668 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
